

PRIMACOVID[®]

COVID-19 NEUTRALISING IgG SEROLOGICAL TEST


Rapid self-test for the qualitative detection of COVID-19 antibodies produced after vaccination in human whole blood samples

PRIMA[®]
HOME TEST

Result in 10 minutes



CE
0483



Test your health

SPIKE PROTEIN

One of the most important proteins involved in the virus infection process is the Spike protein, which covers the whole virus' surface. It is divided into two portions: the first one contains a region known as RBD (Receptor Binding Domain) that allows the virus to bind to the host cell by adhering to the ACE2 receptor; while the second one allows the virus to enter the cell in a following phase. This evidence allows us to assume that an antibody capable of inhibiting the interaction between the Spike protein and the ACE2 receptor would potentially prevent coronavirus infection and the associated disease.

WHO ARE THE INTENDED USERS

COVID-19 NEUTRALISING IgG SEROLOGICAL TEST is intended for anyone who wants to test their immune response following vaccination. It is advisable to do the test starting from 14 days after the end of the vaccination cycle.

WHY - BENEFITS

It is increasingly important to support the ongoing vaccination campaigns, by checking the immune response post-vaccination.

TEST PRINCIPLE

COVID-19 NEUTRALISING IgG SEROLOGICAL TEST is a rapid immunochromatographic assay, whose target analyte are IgG antibodies against the RBD (Receptor Binding Domain) portion of the SARS-CoV-2 Spike protein. This portion allows the virus to bind to the host cell.

TECH SPECS


SEROCONV. PFIZER	SEROCONV. MODERNA	SEROCONV. ASTRAZENECA
98.3%	95.2%	98.5%

CLINICAL EVIDENCES


1. European Centre for Disease Prevention and Control, Disease background of COVID-19 (<https://www.ecdc.europa.eu/en/2019-ncov-background-disease>)
2. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
3. HUANG, Yuan, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacologica Sinica*, 2020, 41.9: 1141-1149.
4. SHANG, Jian, et al. Structural basis of receptor recognition by SARS-CoV-2. *Nature*, 2020, 581.7807: 221-224
5. Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020). Immunological considerations for COVID-19 vaccine strategies. *Nature Reviews Immunology*, 20(10), 615-632.

HOW TO USE IT


1) Take a blood sample after pricking the finger.



2) Deposit the sample into the specimen well of the cassette.



3) Add 2 drops of diluent and wait 10 minutes before reading the result.



CONTENT: 1 sealed aluminium pouch containing: 1 test device and 1 desiccant bag; 1 transparent plastic bag containing a pipette for blood collecting; 1 vial with dropper containing the diluent; 2 sterile lancets for blood sampling; 1 alcohol swab and 1 instructions for use leaflet.

REF	DESCRIPTION	NUMBER OF TESTS
800165-1	COVID-19 NEUTRALISING IgG SEROLOGICAL TEST	1 TEST